Implications of Different CA 15-3 Levels according to Breast Cancer Subtype at Initial Diagnosis of Recurrent or Metastatic Breast Cancer

Publisher： Karger

E-ISSN： 1423-0232|82|3|180-187

ISSN： 0030-2414

Source： Oncology, Vol.82, Iss.3, 2012-03, pp. : 180-187

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Serum tumour markers CA 15-3, TPA, TPS, hCG β and TATI in the monitoring of chemotherapy response in metastatic breast cancer

By Sjöström J.   Alfthan H.   Joensuu H.   Stenman U.-H.   Lundin J.   Blomqvist C.  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 61, Iss. 6, 2001-09 ,pp. : 431-441

Informa Healthcare

Access to resources Recommend Favorite

Lapatinib in metastatic breast cancer

By Frenel J-S   Bourbouloux E   Berton-Rigaud D   Sadot-Lebouvier S   Zanetti A   Campone M  

Women's Health, Vol. 5, Iss. 6, 2009-11 ,pp. : 603-612

Future Medicine

Access to resources Recommend Favorite

Stage of Presentation at Initial Breast Cancer Diagnosis: Does Race Remain a Factor?

By  

THE BREAST JOURNAL, Vol. 21, Iss. 4, 2015-07 ,pp. : 445-446

John Wiley & Sons Inc

Access to resources Recommend Favorite

Docetaxel Weekly with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 30, Iss. 8-9, 2007-09 ,pp. : 407-408

Karger

Access to resources Recommend Favorite

Xeloda® in the Treatment of Metastatic Breast Cancer

By  

Oncology, Vol. 57, Iss. 1, 1999-07 ,pp. : 16-20

Karger

Access to resources Recommend Favorite